favezelimab/pembrolizumab (MK-4280A) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
2021-001309-60: MK-4280A Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer MK-4280A en comparación con el tratamiento de referencia en pacientes con Cancer Colorrectal metastásico positivo para PD-L1 tratados previamente

Not yet recruiting
3
432
Europe, RoW
favezelimab / pembrolizumab, TRIFLURIDINE / TIPIRACIL, MK-4280A, Solution for infusion, Film-coated tablet, Stivarga 40 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Metastatic Colorectal Cancer cáncer colorrectal metastásico, Metastatic Colorectal Cancer cáncer colorrectal metastásico, Diseases [C] - Cancer [C04]
 
 
2022-000371-39: MK-4280A versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, relapsed/refractory Classical Hodgkin Lymphoma

Ongoing
3
360
Europe
MK4280A (Favezelimab + Pembrolizumab), MK4280A, Solution for infusion, Bendamustine, Gemcitabine
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma, Relapsed or Refractory Classical Hodgkin Lymphoma, Diseases [C] - Cancer [C04]
 
 
KEYFORM-007, NCT05064059: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Active, not recruiting
3
505
Europe, Canada, Japan, US, RoW
favezelimab/pembrolizumab, MK-4280A, regorafenib, STIVARGA®, REGONIX®, TAS-102, LONSURF®
Merck Sharp & Dohme LLC
Colorectal Cancer
08/24
02/25
KEYFORM-007, NCT05600309: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Active, not recruiting
3
94
RoW
favezelimab/pembrolizumab, MK-4280A, regorafenib, STIVARGA®, REGONIX®, TAS-102, LONSURF®
Merck Sharp & Dohme LLC
Colorectal Cancer
08/24
02/25
KEYFORM-008, NCT05508867 / 2022-000371-39: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

Active, not recruiting
3
360
Europe, Canada, US, RoW
favezelimab/pembrolizumab, MK-4820A, bendamustine, BENDEKA®, gemcitabine, GEMZAR®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Hodgkin Lymphoma
05/27
06/31
KEYNOTE-587, NCT03486873 / 2017-004417-42: Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/)

Recruiting
3
3500
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Standard of Care (SOC), Lenvatinib, Olaparib, Lynparza, MK-4280, Favezelimab, MK-4280A
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., MerckSharp&DohmeCorp, a subsidiary of Merck&Co,Inc
Solid Tumors, Hematologic Malignancies
08/43
08/43
KeyImPaCT, NCT03516981 / 2017-003134-85: A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

Active, not recruiting
2
318
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Favezelimab, MK-4280, Lenvatinib, MK-7902, Quavonlimab, MK-1308
Merck Sharp & Dohme LLC
Advanced Non-Small Cell Lung Cancer
11/25
11/25
KEYSTEP-008, NCT04895722 / 2020-005114-18: Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/)

Active, not recruiting
2
320
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, Keytruda®, Pembrolizumab/Quavonlimab, MK-1308A, Pembrolizumab/Favezelimab, MK-4280A, Pembrolizumab/Vibostolimab, MK-7684A, MK-4830
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Colorectal Cancer
06/26
06/27
KEYNOTE-057, NCT02625961 / 2014-004026-17: Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/)

Checkmark From KEYNOTE-057 trial in NMIBC
Jun 2021 - Jun 2021: From KEYNOTE-057 trial in NMIBC
Checkmark KEYNOTE-057 trial in NMIBC
Dec 2018 - Dec 2018: KEYNOTE-057 trial in NMIBC
Active, not recruiting
2
320
NA
Pembrolizumab, MK-3475, KEYTRUDA, Pembrolizumab/vibostolimab coformulation, MK-7684A, Favezelimab/pembrolizumab coformulation, MK-4280A
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck &
Bladder Cancer
08/26
08/30
KeyForm-010, NCT06036836: Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Active, not recruiting
2
160
Europe, Canada, US, RoW
favezelimab/pembrolizumab, MK-4280A, pembrolizumab, MK-3475, Keytruda®, lenvatinib
Merck Sharp & Dohme LLC
Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer
03/27
03/27
2019-003610-13: A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Substudy 03B

Not yet recruiting
1/2
370
Europe
Lenvatinib, MK-1308/Pembrolizumab, MK-4280/Pembrolizumab, MK-4830, MK-6482, E7080, MK-1308A, MK-4280A, MK-4830, MK-6482, Solution for infusion, Capsule, hard, Film-coated tablet, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme LLC
Renal Cell Carcinoma, Renal Cell Carcinoma (Kidney Cancer), Diseases [C] - Cancer [C04]
 
 
2019-003609-84: A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Substudy 03A

Not yet recruiting
1/2
430
Europe
Lenvatinib, MK-1308/Pembrolizumab, MK-4280/Pembrolizumab, MK-6482, E7080, MK-1308A, MK-4280A, MK-6482, Solution for infusion, Capsule, hard, Film-coated tablet, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme LLC
Renal Cell Carcinoma, Renal Cell Carcinoma (Kidney Cancer), Diseases [C] - Cancer [C04]
 
 
2021-005405-26: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment Studio con disegno a ombrello, di fase 1/2 in aperto, di molecole sperimentali in associazione a Pembrolizumab (MK-3475) in partecipanti con tumore esofageo avanzato naïve al trattamento con PD-1/PD-L1 (KEYMAKER-U06)

Not yet recruiting
1/2
120
Europe
-, MK-4830, favezelimab / pembrolizumab, Lenvatinib, [MK-3475], [MK-4830], [MK-4280A], [E7080], [-], Solution for infusion, Capsule, hard, Concentrate for solution for injection/infusion, KEYTRUDA® (Pembrolizumab, MK-3475), Paclitaxel, Irinotecan
MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma (ESCC) Carcinoma a cellule squamose dell'esofago (ESCC), Advance esophageal carcinoma Carcinoma esofageo avanzato, Diseases [C] - Cancer [C04]
 
 
2022-001371-14: A Phase 1/2, Umbrella Study of the Efficacy and Safety of Pembrolizumab plus Enfortumab vedotin +/- Investigational Agents in First-Line metastatic urothelial carcinoma

Ongoing
1/2
390
Europe
MK-7684A, MK-4280A, MK-7684A, MK-4280A, Powder for concentrate for solution for infusion, Solution for infusion, Solution for solution for infusion, Padcev, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Locally advanced/unresectable or metastatic urothelial carcinoma previously untreated for their advanced disease, Locally advanced or metastatic bladder cancer, Diseases [C] - Cancer [C04]
 
 
KEYMAKER-U06 substudy 06A, NCT05342636: A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Active, not recruiting
1/2
120
Europe, Japan, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Coformulation favezelimab/pembrolizumab, MK-4280A, MK-4830, anti-immunoglobulin-like transcript 4 (ILT4), Lenvatinib, MK-7902, LENVIMA®, Irinotecan, Paclitaxel
Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma (ESCC)
03/25
09/26
LIGHTBEAM-U01, NCT06395090: A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/)

Withdrawn
1/2
60
US, RoW
Pembrolizumab, MK-3475, Favezelimab, Favezelimab/Pembrolizumab, MK-4280A, Vibostolimab, Pembrolizumab/Vibostolimab, MK-7684A
Merck Sharp & Dohme LLC
Neoplasm Metastasis
06/29
06/29
KEYMAKER-U03B, NCT04626518: Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

Active, not recruiting
1/2
370
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, MK-4830, Belzutifan, MK-6482, WELIREG™, Lenvatinib, MK-7902, E7080, LENVIMA®, Pembrolizumab/Quavonlimab, MK-1308A, Favezelimab/Pembrolizumab, MK-4280A
Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
09/25
09/25
MK-3475-03A, NCT04626479: Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma

Active, not recruiting
1/2
400
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Favezelimab/Pembrolizumab, MK-4280A, Belzutifan, MK-6482, WELIREG™, Lenvatinib, MK-7902, E7080, LENVIMA®, Pembrolizumab/Quavonlimab, MK-1308A, Vibostolimab/Pembrolizumab, MK-7684A
Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
05/26
05/26
KEYNOTE-B98, NCT04938817 / 2020-005628-12: Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/)

Recruiting
1/2
110
Europe, Canada, US, RoW
coformulation pembrolizumab/quavonlimab, MK-1308A, lenvatinib, LENVIMA®, KISPLYX®, MK-7902, E7080, MK-4830, coformulation favezelimab/pembrolizumab, MK-4280A, R-DXd
Merck Sharp & Dohme LLC, Daiichi Sankyo
Small Cell Lung Carcinoma
05/26
12/29
KEYMAKER-U04 Substudy, NCT05845814 / 2022-001371-14: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

Active, not recruiting
1/2
390
Europe, Canada, US, RoW
Coformulated favezelimab/pembrolizumab, MK-4280A, Coformulated vibostolimab/pembrolizumab, MK-7684A, EV, Padcev, ASG-22CE, ASG-22ME, Pembrolizumab, MK-3475, KEYTRUDA®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Metastatic Urothelial Carcinoma, Urothelial Neoplasms
05/27
05/27
KEYMAKER-U02 Substudy 02C, NCT04303169: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Active, not recruiting
1/2
90
Europe, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Vibostolimab, MK-7684, Gebasaxturev, Coxsackievirus A21 (CVA21), Formerly known as CAVATAK®, CAV21, V937, MK-4830, Favezelimab + Pembrolizumab, MK-4280A, ATRA, Tretinoin, Vesanoid®
Merck Sharp & Dohme LLC
Melanoma
04/30
04/30
KEYMAKER-U02 Substudy 02B, NCT04305054 / 2019-003977-24: Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Recruiting
1/2
315
Europe, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Vibostolimab, MK-7684, Pembrolizumab/Quavonlimab, MK-1308A, Lenvatinib, MK-7902, E7080, LENVIMA®, Favezelimab/Pembrolizumab, MK-4280A, ATRA
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck &, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme LLC
Melanoma
04/30
04/30
MK-4280-001, NCT02720068: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors

Completed
1
482
NA
Favezelimab, MK-4280, Pembrolizumab, MK-3475, KEYTRUDA®, Oxaliplatin, ELOXATIN®, Irinotecan, CAMPTOSAR®, Leucovorin (Calcium Folinate), WELLCOVORIN®, Fluorouracil [5-FU], ADRUCIL®, Favezelimab/Pembrolizumab, MK-4280A, Lenvatinib, E7080, MK-7902, LENVIMA®
Merck Sharp & Dohme LLC
Neoplasms
03/24
03/24

Download Options